Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 2/2021

Open Access 01-02-2021 | Olodaterol | Review

Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-/Pooled Analyses

Authors: François Maltais, Alberto de la Hoz, Richard Casaburi, Denis O’Donnell

Published in: Advances in Therapy | Issue 2/2021

Login to get access

Abstract

One of the most debilitating symptoms of chronic obstructive pulmonary disease (COPD) is breathlessness, which leads to avoidance of physical activities in daily living and hastens clinical deterioration. Treatment of patients with COPD with inhaled long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) combination therapy improves airflow limitation, reduces breathlessness compared with LAMA or LABA monotherapies, and improves health status and quality of life. A large clinical trial programme focusing on the effects of tiotropium/olodaterol combination therapy demonstrated that this LAMA/LABA combination improves lung function and reduces hyperinflation (assessed by serial inspiratory capacity measurements) compared with either tiotropium alone or placebo in patients with COPD. Tiotropium/olodaterol also increases exercise endurance capacity and improves patient perception of the intensity of breathlessness compared with placebo. In this narrative review, we focus on the relationship between improving symptoms during activity, the ability to remain active in daily life and how this may impact quality of life. We consider the benefits of therapy optimisation by means of dual bronchodilation with tiotropium/olodaterol, and present new data from meta-analyses/pooled analyses showing that tiotropium/olodaterol improves inspiratory capacity compared with placebo and tiotropium and improves exercise endurance time compared with placebo after 6 weeks of treatment. We also discuss the importance of taking a holistic approach to improving physical activity, including pulmonary rehabilitation and exercise programmes in parallel with bronchodilator therapy and psychological programmes to support behaviour change.

Graphic Abstract

Literature
1.
Troosters T, Sciurba F, Battaglia S, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med. 2010;104(7):1005–11.PubMedPubMedCentralCrossRef
2.
Marchetti N, Kaplan A. COPD in primary care: key considerations for optimized management: dyspnea and hyperinflation in chronic obstructive pulmonary disease: impact on physical activity. J Fam Pract. 2018;67(2 Suppl):S3–10.PubMed
3.
Hanania NA, O’Donnell DE. Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions. Int J Chronic Obstr Pulm Dis. 2019;14:1127–38.CrossRef
4.
Dekhuijzen R, Hass N, Liu J, Dreher M. Daily impact of COPD in younger and older adults: global online survey results from over 1300 patients. COPD. 2020;17(4):419–28.
5.
Hutchinson A, Barclay-Klingle N, Galvin K, Johnson MJ. Living with breathlessness: a systematic literature review and qualitative synthesis. Eur Respir J. 2018;51(2):1701477.PubMedCrossRef
6.
Ramon MA, Ter Riet G, Carsin AE, et al. The dyspnoea-inactivity vicious circle in COPD: development and external validation of a conceptual model. Eur Respir J. 2018;52(3):1800079.PubMedCrossRef
7.
Palange P, Ward SA, Carlsen KH, et al. Recommendations on the use of exercise testing in clinical practice. Euro Respir J. 2007;29(1):185–209.CrossRef
8.
Casaburi R. Activity promotion: a paradigm shift for chronic obstructive pulmonary disease therapeutics. Proc Am Thorac Soc. 2011;8(4):334–7.PubMedCrossRef
9.
Gea J, Pascual S, Casadevall C, Orozco-Levi M, Barreiro E. Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings. J Thorac Dis. 2015;7(10):E418–38.PubMedPubMedCentral
10.
Moxham J, Jolley C. Breathlessness, fatigue and the respiratory muscles. Clin Med. 2009;9(5):448–52.CrossRef
11.
Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61(9):772–8.PubMedPubMedCentralCrossRef
12.
ZuWallack R, Esteban C. Understanding the impact of physical activity in COPD outcomes: moving forward. Eur Respir J. 2014;44(5):1107–9.PubMedCrossRef
13.
Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140(2):331–42.PubMedCrossRef
14.
Mullerova H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One. 2014;9(1):e85540.PubMedPubMedCentralCrossRef
15.
Albarrati AM, Gale NS, Munnery MM, Cockcroft JR, Shale DJ. Daily physical activity and related risk factors in COPD. BMC Pulm Med. 2020;20(1):1–8.CrossRef
16.
17.
Troosters T, Maltais F, Leidy N, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(8):1021–32.PubMedCrossRef
18.
Anzueto A, Miravitlles M. The role of fixed-dose dual bronchodilator therapy in treating COPD. Am J Med. 2018;131(6):608–22.PubMedCrossRef
19.
Rogliani P, Calzetta L, Braido F, et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J Chronic Obstr Pulm Dis. 2018;13:3115–30.CrossRef
20.
Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45(4):969–79.PubMedPubMedCentralCrossRef
21.
Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53–9.PubMedCrossRef
22.
Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312–9.PubMedCrossRef
23.
Jones P, Miravitlles M, van der Molen T, Kulich K. Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement. Int J Chronic Obstr Pulm Dis. 2012;7:697–709.CrossRef
24.
Garcia-Rio F, Lores V, Mediano O, et al. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med. 2009;180(6):506–12.PubMedCrossRef
25.
26.
Thomas M, Decramer M, O’Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Primary Care Respir J. 2013;22(1):101–11.CrossRef
27.
Langer D, Ciavaglia CE, Neder JA, Webb KA, O’Donnell DE. Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment. Expert Rev Respir Med. 2014;8(6):731–49.PubMedCrossRef
28.
O’Donnell DE, Casaburi R, Frith P, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017;49(4):1601348.PubMedPubMedCentralCrossRef
29.
Maltais F, O’Donnell D, Galdiz Iturri JB, et al. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2018;12:1–13.CrossRef
30.
Maltais F, Aumann JL, Kirsten A-M, et al. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. Eur Respir J. 2019;53(3):1802049.PubMedPubMedCentralCrossRef
31.
Vilaró J, Resqueti VR, Fregonezi GAF. Clinical assessment of exercise capacity in patients with chronic obstructive pulmonary disease. Brazil J Phys Ther. 2008;12(4):249–59.CrossRef
32.
Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416–69.PubMedCrossRef
33.
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–7.CrossRef
34.
Celli B, Tetzlaff K, Criner G, et al. The 6-minute-walk distance test as a chronic obstructive pulmonary disease stratification tool. Insights from the COPD Biomarker Qualification Consortium. Am J Respir Crit Care Med. 2016;194(12):1483–93.PubMedPubMedCentralCrossRef
35.
Puente-Maestu L, Palange P, Casaburi R, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J. 2016;47(2):429–60.PubMedCrossRef
36.
Borenstein M, Hedges L, Higgins J, Rothstein H. Introduction to meta-analysis. Chichester: Wiley; 2009.CrossRef
37.
O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–40.PubMedCrossRef
38.
Borg G. Psychophysical scaling with applications in physical work and the perception of exertion. Scand J Work Environ Health. 1990;16(Suppl 1):55–8.CrossRefPubMed
39.
Hareendran A, Leidy NK, Monz BU, Winnette R, Becker K, Mahler DA. Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD. Int J Chronic Obstr Pulm Dis. 2012;7:345–55.CrossRef
40.
Williams N. The Borg Rating of Perceived Exertion (RPE) scale. Occup Med. 2017;67(5):404–5.CrossRef
41.
Sava F, Perrault H, Brouillard C, et al. Detecting improvements in dyspnea in COPD using a three-minute constant rate shuttle walking protocol. COPD. 2012;9(4):395–400.PubMedCrossRef
42.
Perrault H, Baril J, Henophy S, Rycroft A, Bourbeau J, Maltais F. Paced-walk and step tests to assess exertional dyspnea in COPD. COPD. 2009;6(5):330–9.PubMedCrossRef
43.
Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407–11.PubMedCrossRef
44.
Troosters T, Bourbeau J, Maltais F, et al. Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design. BMJ Open. 2016;6(4):e010106.PubMedPubMedCentralCrossRef
45.
Jones GL. Quality of life changes over time in patients with chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2016;22(2):125–9.PubMedCrossRef
46.
Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–64.PubMedCrossRef
47.
McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;2:CD003793.
48.
Leidy NK, Kimel M, Ajagbe L, Kim K, Hamilton A, Becker K. Designing trials of behavioral interventions to increase physical activity in patients with COPD: insights from the chronic disease literature. Respir Med. 2014;108(3):472–81.PubMedCrossRef
49.
Corhay JL, Dang DN, Van Cauwenberge H, Louis R. Pulmonary rehabilitation and COPD: providing patients a good environment for optimizing therapy. Int J Chronic Obstr Pulm Dis. 2014;9:27–39.
50.
Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest. 2007;131(5):4S-42S.PubMedCrossRef
51.
Osadnik CR, Loeckx M, Louvaris Z, et al. The likelihood of improving physical activity after pulmonary rehabilitation is increased in patients with COPD who have better exercise tolerance. Int J Chronic Obstr Pulm Dis. 2018;13:3515–27.CrossRef
52.
Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127(3):809–17.PubMedCrossRef
53.
Kesten S, Casaburi R, Kukafka D, Cooper CB. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chronic Obstr Pulm Dis. 2008;3(1):127–36.CrossRef
54.
Bourbeau J, Lavoie KL, Sedeno M. Comprehensive self-management strategies. Semin Respir Crit Care Med. 2015;36(4):630–8.PubMedCrossRef
55.
Sauer R, Hansel M, Buhl R, Rubin RA, Frey M, Glaab T. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study. Int J Chronic Obstr Pulm Dis. 2016;11:891–8.
56.
Rau-Berger H, Mitfessel H, Glaab T. Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease. Int J Chronic Obstr Pulm Dis. 2010;5:367–73.CrossRef
57.
Steinmetz KO, Abenhardt B, Pabst S, et al. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting. Int J Chronic Obstr Pulm Dis. 2019;14:1441–53.CrossRef
58.
Valipour A, Tamm M, Kociánová J, et al. Improvement of self-reported physical functioning with tiotropium/olodaterol in Central and Eastern European COPD patients. Int J Chronic Obstr Pulm Dis. 2019;14:2343–54.CrossRef
59.
Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99–103.PubMedCrossRef
60.
61.
Schunemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement properties and interpretability of the Chronic Respiratory disease Questionnaire (CRQ). COPD. 2005;2(1):81–9.PubMedCrossRef
62.
Puhan MA, Chandra D, Mosenifar Z, et al. The minimal important difference of exercise tests in severe COPD. Eur Respir J. 2011;37(4):784–90.PubMedCrossRef
63.
Singh SJ, Jones PW, Evans R, Morgan MDL. Minimum clinically important improvement for the incremental shuttle walking test. Thorax. 2008;63(9):775–7.PubMedCrossRef
64.
Pepin V, Laviolette L, Brouillard C, et al. Significance of changes in endurance shuttle walking performance. Thorax. 2011;66(2):115–20.PubMedCrossRef
65.
Revill SM, Morgan MDL, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax. 1999;54:213–22.PubMedPubMedCentralCrossRef
66.
Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD. 2005;2(1):105–10.PubMedCrossRef
67.
Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–5.PubMedCrossRef
Metadata
Title
Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-/Pooled Analyses
Authors
François Maltais
Alberto de la Hoz
Richard Casaburi
Denis O’Donnell
Publication date
01-02-2021
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 2/2021
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01557-x

Other articles of this Issue 2/2021

Advances in Therapy 2/2021 Go to the issue

Original Research

Effects of Different Applications of Tranexamic Acid on Perioperative Blood Transfusion Rate and Postoperative Pain in Unilateral Total Knee Arthroplasty

Original Research

The Effects of Acarbose on Non-Diabetic Overweight and Obese Patients: A Meta-Analysis

Review

The Roles of Insulin-Like Growth Factor Binding Protein Family in Development and Diseases

Review

Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review

Original Research

Children and Adults with PFAPA Syndrome: Similarities and Divergences in a Real-Life Clinical Setting

Review

Post Abortion Care and Management After Induced Abortion During the COVID-19 Pandemic: A Chinese Expert Consensus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits